Compare AbbVie Inc (ABBV) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Rockwell Automation — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Rockwell Automation trades at $459.7 (market cap $52.18B). The key difference: AbbVie Inc is far larger — about 8.6× Rockwell Automation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ROK | |
|---|---|---|
Market Cap | $449.91B | $52.18B |
Sector | Health | Industrials |
52-Week High | $261.07 | $495.08 |
52-Week Low | $184.85 | $328.67 |
Enterprise Value | $513.38B | $55.81B |
Dividend Yield | 2.72% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Rockwell Automation (ROK) trades at $468.9, down 0.59% today but near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Revenue remains stable at $8.34B (2025), though net margins have softened to 10.41%. Recent news highlights AI infrastructure opportunities and product launches like FactoryTalk Orchestration, positioning ROK for industrial digital transformation growth.
Outlook remains positive with analyst consensus leaning toward Hold/Buy, targeting $463.86. Key opportunities include AI-driven industrial automation demand, while risks involve margin pressure and cyclical industry exposure. Valuation multiples (P/E 50.14) suggest premium pricing, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
